Mutual of America Capital Management LLC Acquires 5,204 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Mutual of America Capital Management LLC increased its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 16.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 36,602 shares of the biotechnology company’s stock after purchasing an additional 5,204 shares during the period. Mutual of America Capital Management LLC owned 0.06% of Blueprint Medicines worth $3,376,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Raymond James & Associates boosted its holdings in shares of Blueprint Medicines by 18.6% during the first quarter. Raymond James & Associates now owns 31,565 shares of the biotechnology company’s stock worth $2,016,000 after acquiring an additional 4,945 shares during the period. US Bancorp DE boosted its holdings in shares of Blueprint Medicines by 11.4% during the first quarter. US Bancorp DE now owns 7,234 shares of the biotechnology company’s stock worth $463,000 after acquiring an additional 743 shares during the period. MetLife Investment Management LLC boosted its holdings in shares of Blueprint Medicines by 53.9% during the first quarter. MetLife Investment Management LLC now owns 31,782 shares of the biotechnology company’s stock worth $2,030,000 after acquiring an additional 11,131 shares during the period. Rhumbline Advisers boosted its holdings in shares of Blueprint Medicines by 1.5% during the first quarter. Rhumbline Advisers now owns 63,434 shares of the biotechnology company’s stock worth $4,052,000 after acquiring an additional 924 shares during the period. Finally, BlackRock Inc. boosted its holdings in shares of Blueprint Medicines by 0.9% during the first quarter. BlackRock Inc. now owns 5,383,138 shares of the biotechnology company’s stock worth $343,876,000 after acquiring an additional 46,264 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. JMP Securities restated a “market outperform” rating and set a $114.00 price objective on shares of Blueprint Medicines in a report on Wednesday, April 10th. Citigroup boosted their price objective on Blueprint Medicines from $54.00 to $65.00 and gave the stock a “sell” rating in a report on Friday, February 16th. Wedbush reiterated an “outperform” rating and issued a $97.00 price target on shares of Blueprint Medicines in a research note on Monday, February 5th. Needham & Company LLC reiterated a “buy” rating and issued a $97.00 price target on shares of Blueprint Medicines in a research note on Monday, February 26th. Finally, Stifel Nicolaus boosted their price target on Blueprint Medicines from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Tuesday, January 9th. Four investment analysts have rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Blueprint Medicines has a consensus rating of “Hold” and a consensus target price of $85.43.

Insider Transactions at Blueprint Medicines

In other news, Director Jeffrey W. Albers sold 25,000 shares of the company’s stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $81.91, for a total transaction of $2,047,750.00. Following the completion of the transaction, the director now directly owns 176,050 shares in the company, valued at $14,420,255.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, COO Christina Rossi sold 6,070 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $90.69, for a total value of $550,488.30. Following the completion of the sale, the chief operating officer now directly owns 64,306 shares in the company, valued at $5,831,911.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey W. Albers sold 25,000 shares of the stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $81.91, for a total value of $2,047,750.00. Following the completion of the sale, the director now owns 176,050 shares of the company’s stock, valued at $14,420,255.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 117,289 shares of company stock worth $10,361,913. Corporate insiders own 3.88% of the company’s stock.

Blueprint Medicines Stock Up 2.7 %

Shares of BPMC opened at $88.38 on Thursday. Blueprint Medicines Co. has a one year low of $43.89 and a one year high of $101.00. The company has a market cap of $5.41 billion, a P/E ratio of -10.57 and a beta of 0.63. The company has a debt-to-equity ratio of 1.60, a current ratio of 3.76 and a quick ratio of 3.66. The firm has a 50 day simple moving average of $89.22 and a two-hundred day simple moving average of $76.96.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating the consensus estimate of ($2.04) by $0.22. The business had revenue of $71.96 million during the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative net margin of 203.30% and a negative return on equity of 191.56%. The company’s revenue was up 85.5% on a year-over-year basis. During the same period in the previous year, the business earned ($2.65) earnings per share. Research analysts forecast that Blueprint Medicines Co. will post -5.42 EPS for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.